Evaluation and Credit: https://www.surveymonkey.com/r/MedChat18
This activity is targeted toward Primary care specialties and psychiatrists.
Statement of Need
Promising research is being conducted on psychedelics for the treatment of psychiatric disorders. Providers should be aware of emerging treatments. This podcast will address the research base and clinical use of psychedelics in the United States. Providers will be informed on the potential for use in practice in the future.
At the conclusion of this offering, the participant will be able to:
ModeratorJohn J. Wernert, M.D., MHA, DLFAPA Executive Medical Norton Behavioral Medicine
SpeakerChristopher D. Bojrab, M.D., DFAPA President Indiana Health Group Carmel, Indiana
The speaker has the following conflicts of interest to disclose: Consultant and Speakers Bureau – Allergan, Assures/Myriad, Neurocrine, Otsuka, Sunovion, Takeda and Teva. All relevant relationships have been successfully resolved.
Moderator and Planner Disclosures
The moderator and planners for this activity have no potential or actual conflicts of interest to disclose.
This activity has not received commercial support.
Continuing Education Credits
American Medical Association
Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians.
Norton Healthcare designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Kentucky Board of Nursing
Kentucky Board of Nursing (KBN) Approved Provider: Norton Healthcare, provider number 4-0002-12-20-245. The program has been approved by Norton Healthcare for 0.6 contact hours which expires 12/31/2020. KBN approval of a continuing education provider does not constitute endorsement of program content. Nursing participants must attest to the number of hours of attendance and complete the evaluation to receive contact hours.
For more information related to nursing credits, contact Sally Sturgeon DNP, RN, SANE-A, AFN-BC at (502) 446-5889 or firstname.lastname@example.org
Date of Original Release | September 2020
Course Termination Date | September 30, 2022
Contact Information | Center for Continuing Medical Education; (502) 446-5955 or email@example.com
Resources for Additional Study
Chi, Tingying and Gold Jessica A., A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses, Journal of the Neurological Sciences, Volume 411, 15, April 2020. https://www.sciencedirect.com/science/article/pii/S0022510X20300514?via%3Dihub
Krediet, Erwin, et.al., Reviewing the Potential of Psychedelics for the Treatment of PTSD, International Journal of Neuropsychopharmacology, March 20, 2020. https://academic.oup.com/ijnp/article/23/6/385/5805249
Romeo, Bruno, et. al, Efficacy of psychedelic treatments on depressive syndromes: A meta-analysis, Journal of Psychopharmacology, May 25, 2020. https://journals.sagepub.com/doi/10.1177/0269881120919957